How to buy ADMA Biologics stock | 2.24

ADMA Biologics, Inc is a biotechnology business based in the US. ADMA Biologics shares (ADMA) are listed on the NASDAQ and all prices are listed in US Dollars. ADMA Biologics employs 313 staff and has a trailing 12-month revenue of around USD$40.3 million.

How to buy shares in ADMA Biologics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for ADMA Biologics. Find the stock by name or ticker symbol: ADMA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ADMA Biologics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.24, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ADMA Biologics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of ADMA Biologics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted ADMA Biologics's share price?

Since the stock market crash in March caused by coronavirus, ADMA Biologics's share price has had significant negative movement.

Its last market close was USD$2.24, which is 38.96% down on its pre-crash value of USD$3.67 and 54.48% up on the lowest point reached during the March crash when the shares fell as low as USD$1.45.

If you had bought USD$1,000 worth of ADMA Biologics shares at the start of February 2020, those shares would have been worth USD$763.10 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$558.61.

ADMA Biologics share price

Use our graph to track the performance of ADMA stocks over time.

ADMA Biologics shares at a glance

• Key figures

Information last updated 2020-11-27.

Latest market close	USD$2.24
52-week range	USD$1.45 - USD$4.79
50-day moving average	USD$2.075
200-day moving average	USD$2.6006
Wall St. target price	USD$8.29
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.243

Buy ADMA Biologics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy ADMA Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ADMA Biologics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ADMA Biologics price performance over time

Historical closes compared with the close of $2.24 from 2020-10-19

1 week (2020-11-24)	21.08%
1 month (2020-10-30)	12.56%
3 months (2020-09-01)	-6.67%
6 months (2020-06-01)	-26.80%

1 year (2019-11-29)	-52.84%
2 years (2018-11-30)	-57.50%
3 years (2017-12-01)	-24.83%
5 years (2015-12-01)	-75.63%

ADMA Biologics financials

Revenue TTM	USD$40.3 million
Gross profit TTM	USD$-10,155,155
Return on assets TTM	-21.17%
Return on equity TTM	-124.48%
Profit margin	-166.01%
Book value	$0.796
Market capitalisation	USD$173 million

TTM: trailing 12 months

Shorting ADMA Biologics shares

There are currently 12.9 million ADMA Biologics shares held short by investors – that's known as ADMA Biologics's "short interest". This figure is 8.3% down from 14.1 million last month.

There are a few different ways that this level of interest in shorting ADMA Biologics shares can be evaluated.

ADMA Biologics's "short interest ratio" (SIR)

ADMA Biologics's "short interest ratio" (SIR) is the quantity of ADMA Biologics shares currently shorted divided by the average quantity of ADMA Biologics shares traded daily (recently around 2.3 million). ADMA Biologics's SIR currently stands at 5.59. In other words for every 100,000 ADMA Biologics shares traded daily on the market, roughly 5590 shares are currently held short.

However ADMA Biologics's short interest can also be evaluated against the total number of ADMA Biologics shares, or, against the total number of tradable ADMA Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ADMA Biologics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 ADMA Biologics shares in existence, roughly 130 shares are currently held short) or 0.1721% of the tradable shares (for every 100,000 tradable ADMA Biologics shares, roughly 172 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ADMA Biologics.

Find out more about how you can short ADMA Biologics stock.

ADMA Biologics share dividends

We're not expecting ADMA Biologics to pay a dividend over the next 12 months.

ADMA Biologics share price volatility

Over the last 12 months, ADMA Biologics's shares have ranged in value from as little as $1.45 up to $4.79. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ADMA Biologics's is 2.0209. This would suggest that ADMA Biologics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

ADMA Biologics overview

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Frequently asked questions

• What percentage of ADMA Biologics is owned by insiders or institutions?

  Currently 2.133% of ADMA Biologics shares are held by insiders and 54.413% by institutions.

• How many people work for ADMA Biologics?

  Latest data suggests 313 work at ADMA Biologics.

• When does the fiscal year end for ADMA Biologics?

  ADMA Biologics's fiscal year ends in December.

• Where is ADMA Biologics based?

  ADMA Biologics's address is: 465 State Route 17, Ramsey, NJ, United States, 07446

• What is ADMA Biologics's ISIN number?

  ADMA Biologics's international securities identification number is: US0008991046

• What is ADMA Biologics's CUSIP number?

  ADMA Biologics's Committee on Uniform Securities Identification Procedures number is: 000899104